Zhejiang Xinguang Pharmaceutical Co., Ltd. (SHE:300519)
13.68
+0.12 (0.88%)
Apr 30, 2025, 3:04 PM CST
SHE:300519 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Operating Revenue | 260.36 | 267.66 | 270.28 | 351.37 | 320.77 | 282.96 | Upgrade
|
Other Revenue | - | - | 0.11 | 0.12 | 0.11 | 0.12 | Upgrade
|
Revenue | 260.36 | 267.66 | 270.4 | 351.49 | 320.88 | 283.08 | Upgrade
|
Revenue Growth (YoY) | -6.56% | -1.01% | -23.07% | 9.54% | 13.35% | -2.81% | Upgrade
|
Cost of Revenue | 173.24 | 177.12 | 160.03 | 169.81 | 145.29 | 128.68 | Upgrade
|
Gross Profit | 87.12 | 90.54 | 110.37 | 181.68 | 175.58 | 154.4 | Upgrade
|
Selling, General & Admin | 42.56 | 41.88 | 43.64 | 50.61 | 49.27 | 46.59 | Upgrade
|
Research & Development | 12.96 | 12.62 | 15.13 | 15.55 | 13.52 | 12.01 | Upgrade
|
Other Operating Expenses | 1.84 | 1.66 | 3.37 | 4.26 | 4.22 | 4.07 | Upgrade
|
Operating Expenses | 57.27 | 56.17 | 61.44 | 70.86 | 66.85 | 62.71 | Upgrade
|
Operating Income | 29.85 | 34.38 | 48.93 | 110.82 | 108.73 | 91.69 | Upgrade
|
Interest & Investment Income | 10.97 | 4.87 | 22.98 | 14.09 | 23.03 | 19.29 | Upgrade
|
Other Non Operating Income (Expenses) | 18.26 | 18.22 | -0.02 | -0.01 | -0.01 | 2.74 | Upgrade
|
EBT Excluding Unusual Items | 59.08 | 57.46 | 71.9 | 124.9 | 131.74 | 113.72 | Upgrade
|
Gain (Loss) on Sale of Assets | -0 | -0.07 | -0.29 | - | -0.71 | - | Upgrade
|
Asset Writedown | -0.11 | -0.39 | 0.02 | 0 | -0.02 | -0.45 | Upgrade
|
Other Unusual Items | - | - | 1.53 | 0.7 | 0.95 | 1.52 | Upgrade
|
Pretax Income | 58.97 | 57.01 | 73.16 | 125.6 | 131.96 | 114.8 | Upgrade
|
Income Tax Expense | 6.87 | 6.62 | 8.8 | 16.78 | 17.68 | 15.82 | Upgrade
|
Net Income | 52.1 | 50.39 | 64.36 | 108.82 | 114.28 | 98.98 | Upgrade
|
Net Income to Common | 52.1 | 50.39 | 64.36 | 108.82 | 114.28 | 98.98 | Upgrade
|
Net Income Growth | -8.18% | -21.70% | -40.86% | -4.78% | 15.46% | 5.41% | Upgrade
|
Shares Outstanding (Basic) | 163 | 163 | 161 | 160 | 161 | 160 | Upgrade
|
Shares Outstanding (Diluted) | 163 | 163 | 161 | 160 | 161 | 160 | Upgrade
|
Shares Change (YoY) | 0.67% | 1.03% | 0.54% | -0.58% | 0.83% | 0.30% | Upgrade
|
EPS (Basic) | 0.32 | 0.31 | 0.40 | 0.68 | 0.71 | 0.62 | Upgrade
|
EPS (Diluted) | 0.32 | 0.31 | 0.40 | 0.68 | 0.71 | 0.62 | Upgrade
|
EPS Growth | -8.79% | -22.50% | -41.18% | -4.23% | 14.52% | 5.08% | Upgrade
|
Free Cash Flow | 53.58 | 48.23 | 37.3 | 109.78 | 127.64 | 102.34 | Upgrade
|
Free Cash Flow Per Share | 0.33 | 0.30 | 0.23 | 0.69 | 0.79 | 0.64 | Upgrade
|
Dividend Per Share | - | - | 0.400 | 0.500 | 0.600 | 0.600 | Upgrade
|
Dividend Growth | - | - | -20.00% | -16.67% | - | 33.33% | Upgrade
|
Gross Margin | 33.46% | 33.83% | 40.82% | 51.69% | 54.72% | 54.54% | Upgrade
|
Operating Margin | 11.47% | 12.84% | 18.10% | 31.53% | 33.88% | 32.39% | Upgrade
|
Profit Margin | 20.01% | 18.83% | 23.80% | 30.96% | 35.62% | 34.96% | Upgrade
|
Free Cash Flow Margin | 20.58% | 18.02% | 13.80% | 31.23% | 39.78% | 36.15% | Upgrade
|
EBITDA | 44.83 | 49.31 | 63.71 | 124.88 | 121.59 | 104.22 | Upgrade
|
EBITDA Margin | 17.22% | 18.42% | 23.56% | 35.53% | 37.89% | 36.82% | Upgrade
|
D&A For EBITDA | 14.97 | 14.93 | 14.77 | 14.05 | 12.86 | 12.53 | Upgrade
|
EBIT | 29.85 | 34.38 | 48.93 | 110.82 | 108.73 | 91.69 | Upgrade
|
EBIT Margin | 11.47% | 12.84% | 18.10% | 31.53% | 33.88% | 32.39% | Upgrade
|
Effective Tax Rate | 11.65% | 11.61% | 12.03% | 13.36% | 13.40% | 13.78% | Upgrade
|
Revenue as Reported | - | - | 270.4 | 351.49 | 320.88 | 283.08 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.